Affiliated Companies
___________________________
AGGREGA Pharma is a specialty generic pharmaceutical company focused on developing, manufacturing and marketing niche, complex, high-barrier-to-entry generic medications (injectable, ophthalmic, ER/IR oral, transdermal, spray, and topical finished dosage forms) for the US Market.
The shareholders are 4 European companies: Bluepharma (Portugal), RAFARM (Greece), Substipharm (France) and Welding (Germany). AGGREGA Pharma is committed to building a selective, valuable pipeline of generic products by leveraging the vast R&D, clinical and manufacturing experience and capabilities of its members.
Our partnership offering is supported by our in-house development and commercial manufacturing facilities at Bluepharma in Portugal and RAFARM in Greece to meet your global product requirements.
MORE INFORMATION
BNSO a subsidiary company of RAFARM
On May 2023, RAFARM and BioNanoSim (BNS), an Israeli-based nanotechnology drug discovery and development company co-founded by Prof. Simon Benita and Yissum -the Transfer Technology and IP company of The Hebrew University of Jerusalem- have entered into an agreement to create a new Ophthalmic company called BNS Ophthalmics (BNSO).
BNSO will develop, manufacture and commercialize a range of innovative ophthalmic pharmaceutical products developed by BioNanoSim to address serious ophthalmic unmet needs for patients around the world. RAFARM will provide appropriate funding, together with infrastructure for development, commercial scale manufacturing and distribution.
BNSO is on track to initiate a phase I/IIa clinical study this year in patients suffering from Chronic Anterior Uveitis, and has two additional preclinical programs in its pipeline. Together, BNSO’s programs target multibillion dollar global market opportunities.
MORE INFORMATION
Related companies to RAFARM
______________________________
RAFARM UK is specialized in the research, development and supply of a wide range of generics with a specific focus on sterile forms, in particular ophthalmic products (solutions, suspensions, emulsions) and complex injectable products.
RAFARM UK is the licensing arm of RAFARM S.A. in UK and US, offering a wide portfolio of products/CTD dossiers to customers interested in in-licensing business model
VELKA Hellas S.A. has a commercial activity in the Greek Pharmaceutical Market, it is a member of RAFARM S.A. Group and operates as an independent company, providing pharmaceutical products for a variety of therapeutic categories and most of healthcare professionals.
VELKA strategic goal is to become the clear proof of a robust, healthy and constantly growing Greek company. These characteristics will ensure high recognition from healthcare professionals and patients, and will corroborate VELKA as a perfect choice for partnership with multinational or local organizations.
MORE INFORMATION
